Testing indapamide to slow disability in progressive MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a daily pill called indapamide, usually used for blood pressure, can help slow down the worsening of symptoms in people with progressive multiple sclerosis. It might help by protecting the nerves, and you would take it for about a year while being monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a diagnosis of primary or secondary progressive MS.
- Your disability level must be moderate, based on a scale from 0 to 10, between 4.0 and 6.5.
- You need to be able to walk (with or without an aid) and take at least 5 to 9 seconds to walk 25 feet, depending on your MS type.
- You must be willing to use effective contraception if you can become pregnant.
- You must not have kidney, liver, or heart problems, low blood pressure, or be pregnant or breastfeeding.
- You must not be taking certain MS medications like ocrelizumab or natalizumab, or have had a recent MRI showing new disease activity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a non-invasive treatment called remote ischemic conditioning can help people with primary progressive multiple sclerosis. You wear a blood pressure cuff on your arm that briefly stops blood flow and then releases it, repeated for several cycles. The goal is to see if this improves walking and other functions.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
This early-phase study tests combination treatments for multiple sclerosis (MS) based on lab “biomarkers” found in the spinal fluid. It aims to reduce ongoing MS activity and help determine which treatment combinations may work best for different people.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.